← Back to Search

Telehealth Navigation for Lung Cancer (TESTING Trial)

N/A

Recruiting

Led By Charu Aggarwal, MD, MPH

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 18 years or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured up to 1 year from the time of randomization to death from any cause

Awards & highlights

TESTING Trial Summary

This trial aims to use telehealth and nurses to get timely, molecularly-informed treatment to patients with lung cancer, plus find ways to make it more effective.

Who is the study for?

This trial is for adults suspected to have advanced lung cancer (NSCLC) based on imaging tests, and who are scheduled for an evaluation. It's not open to those without this type of lung cancer or with another active cancer.Check my eligibility

What is being tested?

The study is testing a telehealth nurse navigation system designed to speed up the process of getting personalized treatment recommendations by using molecular testing early in patient evaluations.See study design

What are the potential side effects?

Since this trial involves a telehealth intervention rather than medication, traditional side effects are not applicable. However, participants may experience issues related to technology use such as privacy concerns or technical difficulties.

TESTING Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

TESTING Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured up to 1 year from the time of randomization to death from any cause

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured up to 1 year from the time of randomization to death from any cause

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured up to 1 year from the time of randomization to death from any cause for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Molecularly-informed treatment recommendations

Secondary outcome measures

Identification of one or more targetable mutations

Intervention costs

Overall survival

+4 more

TESTING Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: TelehealthExperimental Treatment1 Intervention

Patients in the intervention arm will be scheduled for an enhanced synchronous telehealth visit with a trained lung cancer nurse navigator prior to tissue biopsy. The enhanced synchronous telehealth visit will ideally occur between the initial clinical appointment and diagnostic biopsy (typically a period between two and seven days). In addition to the activities conducted as part of usual care, the nurse navigator will: 1) provide more detailed and individualized education on lung cancer and the rationale for comprehensive molecular testing, including plasma-based tests; and 2) if the patient agrees to testing, pend a default order for plasma-based molecular testing (if not already ordered) for the clinician to sign and arrange for phlebotomy to be performed at the time of the patient's tissue biopsy.

Group II: Usual CareActive Control1 Intervention

Patients in the usual care arm will receive a telephone call from a trained lung cancer nurse navigator after biopsy, as is typical at Penn Medicine, to 1) review the roles of clinicians on the medical oncology care team; 2) provide brief education on lung cancer; and 3) review the patient's diagnostic history and coordinate collection or completion of imaging required for guideline-recommended cancer staging. At the initial in-person oncology visit, the oncologist may choose to order plasma-based testing if appropriate (and if not already ordered or pending).

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,526 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,925,716 Total Patients Enrolled

Charu Aggarwal, MD, MPHPrincipal InvestigatorUniversity of Pennsylvania

2 Previous Clinical Trials

522 Total Patients Enrolled

Media Library

Telehealth Clinical Trial Eligibility Overview. Trial Name: NCT05790460 — N/A

Non-Small Cell Lung Cancer Research Study Groups: Telehealth, Usual Care

Non-Small Cell Lung Cancer Clinical Trial 2023: Telehealth Highlights & Side Effects. Trial Name: NCT05790460 — N/A

Telehealth 2023 Treatment Timeline for Medical Study. Trial Name: NCT05790460 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment process for this experiment still open?

"Currently, this clinical trial is not recruiting patients. The study was initially posted on March 20th of 2023 and its most recent update occurred on the 17th of the same month. Nevertheless, 1,579 other medical trials are actively seeking participants at this time."

Answered by AI

What are the objectives of this clinical venture?

"This trial will span 6 weeks with the primary objective being to analyze the efficacy and patient experience. Secondary objectives include pre-treatment molecular testing, identification of targeted mutations, and timely initiation of therapeutic protocols."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

Charu Aggarwal 2023. "Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05790460.